Tarsus Pharmaceuticals (NASDAQ:TARS) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Tarsus Pharmaceuticals (NASDAQ:TARS) to a strong-buy rating in a report released on Monday,Zacks.com reports. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q3 2026 earnings at ($0.24) EPS and Q4 2026 earnings at $0.09 EPS.

Several other brokerages also recently weighed in on TARS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Oppenheimer increased their price target on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Mizuho began coverage on shares of Tarsus Pharmaceuticals in a research note on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Finally, Barclays started coverage on shares of Tarsus Pharmaceuticals in a research report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.83.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $68.24 on Monday. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The stock has a market capitalization of $2.90 billion, a price-to-earnings ratio of -42.12 and a beta of 0.55. The company has a 50-day simple moving average of $69.59 and a 200-day simple moving average of $70.20. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. On average, analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current year.

Insider Buying and Selling

In other news, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $68.79, for a total value of $859,875.00. Following the completion of the sale, the director directly owned 116,332 shares of the company’s stock, valued at $8,002,478.28. This trade represents a 9.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of TARS. Comerica Bank grew its stake in shares of Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after purchasing an additional 705 shares during the period. Truvestments Capital LLC lifted its stake in shares of Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after purchasing an additional 468 shares during the period. Rockefeller Capital Management L.P. lifted its stake in shares of Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after purchasing an additional 172 shares during the period. Osaic Holdings Inc. boosted its holdings in Tarsus Pharmaceuticals by 779.1% during the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after buying an additional 2,462 shares in the last quarter. Finally, Leonteq Securities AG purchased a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $164,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.